Philip Ashton-Rickardt, Ph.D.



  • Founder and CEO, Smith Therapeutics, acquired by AZTherapies in October 2019; inventor of cutting-edge CAR-Treg technology targeting brain glial cells to reduce neuroinflammation associated with neurodegenerative disease such as Alzheimer’s, Parkinson’s, and ALS
  • Esteemed immunologist known for his early findings on T lymphocytes; previously Chair in Immunology at Imperial College London, Visiting Professor, Brigham and Women’s Hospital, Harvard Medical School, and Associate Professor in the Department of Pathology at the University of Chicago
  • Awarded tenure from The University of Chicago; recipient of the Early Career Award for Scientists and Engineers from President Bill Clinton; author of more than 65 peer-reviewed papers in more than 30 academic journals (including Cell, Science, Immunity, and Nature Immunology)
  • B.Sc. in Biochemistry from the University of London, King’s College with honors, Ph.D. in Molecular Biology from the University of Edinburgh; completed post-doctoral work at the University of Edinburgh and the Massachusetts Institute of Technology in Molecular Biology and Molecular Immunology, respectively